Dudek, Arkadiusz Z.
Liu, Li C.
Fischer, James H.
Wiley, Elizabeth L.
Sachdev, Jasgit C.
Bleeker, Jonathan
Hurley, Randolph W.
Tonetti, Debra A.
Thatcher, Gregory R. J.
Venuti, Robert P.
O’Regan, Ruth M.
Clinical trials referenced in this document:
Documents that mention this clinical trial
Phase 1 study of TTC-352 in patients with metastatic breast cancer progressing on endocrine and CDK4/6 inhibitor therapy
https://doi.org/10.1007/s10549-020-05787-z
Funding for this research was provided by:
TTC Oncology
Engdahl Family Foundation
Article History
Received: 17 May 2020
Accepted: 2 July 2020
First Online: 22 July 2020
Compliance with ethical standards
:
: AZD serves as Chief Medical Officer and obtained honoraria from TTC Oncology and Vanquish Oncology. AZD has received honoraria for consulting work from EMD Serono. AZD has equity in TTC Oncology, IGF Oncology, Squarex, and Martell Diagnostic Laboratories. AZD reports research funding to institutions from Merck, and Eli Lilly. DAT and GRJT have equity in TTC Oncology. RPV has received honoraria from TTC Oncology. RMO serves as an advisor for Lilly, PUMA, Novartis, Genomic Health and Biotheranostics and receives grant support from PUMA, Novartis, Seattle Genetics, and Eisai. All other authors declare no competing interests.
: This clinical trial was approved by the Institutional Review Board at the participating institutions. It was conducted in accordance with the Declaration of Helsinki.
: All participants provided written informed consent.